(WASHINGTON) -- Healthcare company Novo Nordisk has announced that it has reached an agreement with the US Department of Justice and two individuals in a civil lawsuit which alleged that the company engaged in improper marketing practices in the United States.
In a statement released Friday, Novo Nordisk said it will pay $25 million to the settlement parties in the lawsuit case regarding improper marketing practices involving the company’s NovoSeven product.
On Friday it was also announced that Novo Nordisk had reached a civil settlement agreement with U.S. Attorneys, that would see the company paying $1.725 million to the U.S. government and several states to resolve allegations about Novo Nordisk’s involvement in the submission of false or fraudulent claims to the Medicaid program in connection with its marketing of the diabetes drugs Novolin, Novolin 70/30, Novolog, and Novolog 70/30, according to an FBI press release.
Copyright 2011 ABC News Radio